Boston Therapeutics
is a pharmaceutical company focused on the development, manufacturing, and
commercialization of novel compounds based on complex carbohydrate chemistry to
address unmet medical needs in diabetes.
PAZ320 is an
integral part of the company’s initial product pipeline, which is focused on
developing and commercializing therapeutic molecules. PAZ320 is a non-systemic,
non-toxic, chewable drug which inhibits the enzymes that release glucose from
complex carbohydrates in foods during digestion, reducing the amount of
available glucose absorbed through the intestine.
In November, Boston
Therapeutics enrolled 24 patients with Type 2 diabetes in a Phase IIb clinical
study on PAZ320, and positive results from the trial were published by the
principal investigator in the July/August issue of the journal “Endocrine
Practice”. After evaluating the safety and efficacy of PAZ320, it was shown
that there was a significant 40% reduction in elevation of post-meal blood
glucose in the participating patients, with no serious adverse events.
By the second or
third quarter of 2014, the company hopes to begin an important Phase III trial
of the chewable tablet it is promoting as a potential adjunct to metformin in
patients living with Type 2 diabetes. While the Phase IIb trial was held only
in France, the Phase III trial will be multi-national–in the United States,
Europe, Hong Kong, and China.
The company believes
that PAZ320 is a safe and effective drug compound for people with pre-diabetes
and diabetes in their daily management of blood glucose levels, fulfilling an
unmet medical need. The intent is for this compound to provide individuals with
a means by which to slow the onset of Type 2 diabetes and/or the onset of
diabetes complications such as heart disease, stroke, kidney damage,
retinopathy, and Diabetic Foot.
PAZ320 is meant to
be taken before meals and works in the gastrointestinal tract to block the
action of carbohydrate-hydrolyzing enzymes that break down complex
carbohydrates into simple sugars, reducing the availability of glucose for
absorption into the bloodstream.
For more information
about PAZ320 or any of the company’s other products, visit the website at
www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment